Clinical trials: Respiratory Infection Virus
Change; Endoscopy, COVID-19
Endoscopic Interventions in Patients With COVID-19
This is a combined study including a descriptive part about the preparations for COVID-19 and the impact of COVID-19 on the daily routine of the work in an Interdisciplinary Endoscopic Unit (IEU), and a point-prevalence analysis…
- Trial name
- NCT04423003
- Testing
- Endoscopic intervention
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital Tuebingen
Sars-CoV2, COVID-19
Implementation of Physiotherapy on COVID-19 Patients in ICU
Despite new charachersitics of COVID-19 patients, critical care implementation seems to be similar to those with Acute Respiratory Distress Syndrome (ARDS) in intensive care units (ICU).
- Trial name
- PHYSIO-COVID (NCT04347070)
- Testing
- Phsyiotherapy
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Montpellier
COVID-19
Availability and Advice on Test Uptake During the COVID-19 Pandemic: a Vignette Study.
Lateral Flow Testing (LFT) use for COVID-19 related symptoms continues to rise, despite governmental advice to test at a test facility.
- Trial name
- NCT05215483
- Testing
- Customised testing advice, Regular testing advice, LFT available
- Where
- Netherlands
- Volunteers
- 3,270 people, healthy volunteers welcome
- Sponsor
- National Institute for Public Health and the Environment (RIVM)
Vaccination Reaction
Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine
The effect of LiteVax Adjuvant supplemented to licensed seasonal influenza vaccine on safety and immunogenicity will be investigated in both younger and older healthy participants.
- Trial name
- TETRALITE-Ib (NCT06294262)
- Testing
- TETRALITE
- Where
- Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- LiteVax BV
Respiratory Distress Syndrome, Adult, COVID-19
Determine the Effects of Prone Positioning and NO in COVID-19 ARDS by EIT
We aims to investigate the effects of prone positioning and nitric oxide inhalation in adult patients who is diagnosed with COVID-19 associated acute respiratory distress syndrome by electrical impedance tomography.
- Trial name
- NCT05715762
- Testing
- prone postion, NO inhalation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
COVID-19
Treating COVID-19 With Hydroxychloroquine (TEACH)
Treatments for COVID-19 are urgently needed. Hydroxychloroquine (HCQ) is an antimalarial and immunomodulatory agent being repurposed for COVID-19 therapy based off in vitro data suggesting a possible antiviral effect.
- Trial name
- NCT04369742
- Testing
- Hydroxychloroquine (HCQ)
- Where
- 2 sites in United States
- Volunteers
- 128 people
- Sponsor
- NYU Langone Health
Infections, Respiratory, Fever
Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals
Operational project to compare clinician collected nasopharyngeal (NP) samples to patient-obtained tongue, nasal and mid-turbinate (MT) samples in the detection of SARS-CoV-2 in an outpatient clinic setting
- Conditions
- Infections, Respiratory, Fever, Cough
- Trial name
- NCT04321369
- Testing
- Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals
- Where
- United States
- Volunteers
- 530 people
- Sponsor
- UnitedHealth Group
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
Evaluate Safety, Tolerability and Immune Response of Adjuvanted H5N1 Cell Culture Derived Influenza Vaccine in Adult Subjects.
- Trial name
- NCT01776541
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 979 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
COVID-19
Geriatric COVID-19 Serology
Coronaviruses are important human and animal pathogens. At the end of 2019, a new coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in China's Hubei province.
- Trial name
- SeroGerCov (NCT05109546)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Influenza
Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects
To evaluate the safety, tolerability and pharmacokinetics (PK) of single,and repeat escalating doses of FF-3 dry powder administered via inhalation in healthy adult subjects
- Trial name
- NCT01990846
- Testing
- Flufirvitide 3
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Autoimmune Technologies, LLC
Pneumonia, Viral
Steroid and Anticoagulant Therapy in covid19
As COVID-19 has neither standard treatment protocol nor guidelines, there are many treatment protocols foranti-inflammatory corticosteroids and anti-coagulations for severe COVID-19 pneumonia patients.
- Trial name
- SARS-CoV-2 (NCT05021588)
- Testing
- steroid and anticoagulants according to different protocols.
- Where
- Egypt
- Volunteers
- 123 people
- Sponsor
- Assiut University
Persistent COVID Condition
Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)
Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden.
- Trial name
- NCT07295483
- Testing
- BioICOPER Long COVID Cohort
- Where
- Spain
- Volunteers
- 400 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
COVID-19
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
Investigational New Drug trial investigating safety as primary endpoint and clinical efficacy as secondary endpoint of placental, mesenchymal stem cell-derived extracellular vesicles for the treatment of COVID-19 symptoms in…
- Trial name
- NCT07664696
- Testing
- IV infusion using an isolated, placental, mesenchymal stem cell derived EVs
- Volunteers
- 64 people
- Sponsor
- Kimera Labs Inc.
Immunosenescence
Fasting-mimicking Diet and Immunosenescence
The objective of this study is to test a Fasting-Mimicking Diet (FMD) for its efficacy on improving immune response to flu vaccination in an older adult population (50-75 years of age).
- Trial name
- NCT02554188
- Testing
- Seasonal influenza (flu) vaccine, Diet
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Southern California
Anxiety, Stress
Assessment of Stress and Associated Factors Among Young Adults During the COVID-19 Pandemic
Since the onset of COVID-19, studies conducted on the general population have shown an increase in the use of antidepressants and anxiolytics, a rise in domestic violence, and heightened demand for peri-urban housing offering…
- Conditions
- Anxiety, Stress, COVID - 19
- Trial name
- JADESTRESS (NCT07845396)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 1,322 people, healthy volunteers welcome
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
COVID-19
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
The scope of this Phase I/II study is to determine whether GLB-COV2-043 is a promising booster vaccine candidate component for adult participants who have received the 2-dose priming course of the mRNA BNT162b2 vaccine against…
- Trial name
- NCT05602961
- Testing
- GLB-COV2-043, BNT162b2/COMIRNATY®
- Volunteers
- healthy volunteers welcome
- Sponsor
- GreenLight Biosciences, Inc.
COVID-19 Pandemic
NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)
This is a prospective, multicenter, randomized (3:1), placebo- controlled, parallel-group, double-blind trial. Patients will be randomized into two arms of treatment: Placebo + SoC (N=30) NanoManganese® + SoC (N=90) Patients will…
- Trial name
- NCT05451654
- Testing
- Experimental drug
- Where
- Brazil
- Volunteers
- 7 people
- Sponsor
- Medesis Pharma SA
Influenza
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
The objectives of this study were: To describe the safety of each dosage of high-dose quadrivalent influenza vaccine (QIV-HD) used in the study during the 28 days following each vaccination, and serious adverse events (including…
- Trial name
- QHD04 (NCT03698279)
- Testing
- High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)
- Where
- 16 sites in United States, Canada
- Volunteers
- 665 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU
The main purpose of the this study is to evaluate the safety and tolerability of Immunose™ FLU based on Endocine™ and quadrivalent influenza antigen.
- Trial name
- NCT02998996
- Testing
- 15 µg HA/strain and 1% Endocine™, 15 µg HA/strain and 2% Endocine™, 15 µg HA/strain
- Where
- 2 sites in Sweden
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Eurocine Vaccines AB
Coronavirus Disease 2019 (COVID-19)
Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.
A randomized, open-label, multicenter, three-arm clinical trial to study the efficacy and safety of passive immunotherapy (convalescent plasma and anti-COVID-19 human immunoglobulin) compared to the standard treatment in Colombia.
- Trial name
- NCT04395170
- Testing
- COVID-19 convalescent plasma, Anti-COVID-19 human immunoglobulin, Standard (specific) therapy for COVID-19
- Where
- Colombia
- Volunteers
- 75 people
- Sponsor
- Lifefactors Zona Franca, SAS